Eli Lilly and Company to Acquire Prevail Therapeutics

Zymeworks Acquires Theravance Biopharma

June 29, 2026

Biotechnology

Zymeworks agreed to acquire all outstanding equity of Theravance Biopharma for $17 per share in cash, representing an announced transaction value of approximately $929 million. Theravance shareholders are also entitled to a contingent value right covering 80% of net proceeds from any future monetization of ampreloxetine; Zymeworks completed the acquisition on September 23, 2026.

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Eli Lilly Acquires Centessa Pharmaceuticals

March 31, 2026

Biotechnology

Eli Lilly and Company entered into a definitive agreement to acquire clinical-stage biopharma Centessa Pharmaceuticals plc for $38.00 per share in cash, plus a non-transferrable contingent value right (CVR) that could bring total consideration to up to $47.00 per share. The deal is structured as a scheme of arrangement under the laws of England and Wales and was expected to close in Q3 2026, subject to shareholder and regulatory approvals and court sanction.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.

Eli Lilly Acquires Adverum Biotechnologies

December 9, 2025

Biotechnology

Eli Lilly and Company agreed to acquire Adverum Biotechnologies in a cash-and-contingent-value-rights tender offer for all outstanding shares. The total consideration is $3.56 per share in cash at closing plus a CVR that could pay up to $8.91 per share upon achievement of specified milestones, with the transaction expected to close in the fourth quarter of 2025.

AbbVie Acquires Cerevel Therapeutics

December 6, 2023

Pharmaceuticals

AbbVie (AbbVie Inc.) announced it will acquire Cerevel Therapeutics in a definitive agreement, strengthening its neuroscience pipeline with multiple clinical- and preclinical-stage programs. The deal values Cerevel at about $8.7 billion and is structured as an all-cash purchase of all outstanding Cerevel shares for $45.00 per share.